% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Steen:285669,
author = {S. Steen and K. Semmelmayer and C. Flechtenmacher and J.
Hoffmann and K. Freier and D. Horn and J. Hess$^*$ and C.
Freudlsperger and J. Moratin},
title = {{D}ynamic {U}p-{R}egulation of {PD}-{L}1 in the
{P}rogression of {O}ral {S}quamous {C}ell {C}arcinoma.},
journal = {International journal of molecular sciences},
volume = {24},
number = {22},
issn = {1422-0067},
address = {Basel},
publisher = {Molecular Diversity Preservation International},
reportid = {DKFZ-2023-02492},
pages = {16386},
year = {2023},
abstract = {The introduction of immune checkpoint inhibition for
recurrent and metastatic head and neck cancer has brought a
new treatment option for patients suffering from advanced
oral cancers without a chance for curation using surgery or
radiotherapy. The application of immune checkpoint
inhibitors in most cases is based on the expression levels
of PD-L1 in the tumor tissue. To date, there is a lack of
data on the dynamic regulation of PD-L1 during disease
progression. Therefore, this study aimed to evaluate the
expression levels of PD-L1 in a large cohort of patients (n
= 222) with oral squamous cell carcinoma including primary
and recurrent tumors. Semiautomatic digital pathology
scoring was used for the assessment of PD-L1 expression
levels in primary and recurrent oral squamous cell
carcinoma. Survival analysis was performed to evaluate the
prognostic significance of the protein expression at
different stages of the disease. We found a significant
up-regulation of PD-L1 expression from primary disease to
recurrent tumors (mean PD-L1 H-scores: primary tumors: 47.1
± 31.4; recurrent tumors: 103.5 ± 62.8, p < 0.001). In
several cases, a shift from low PD-L1 expression in primary
tumors to high PD-L1 expression in recurrent tumors was
identified. Multivariate Cox regression analysis did not
reveal a significantly higher risk of death (p = 0.078) or
recurrence (p = 0.926) in patients with higher PD-L1
expression. Our findings indicate that the exclusive
analysis of primary tumor tissue prior to the application of
checkpoint blockade may lead to the misjudgment of PD-L1
expression in recurrent tumors.},
keywords = {Humans / Squamous Cell Carcinoma of Head and Neck /
Carcinoma, Squamous Cell: pathology / B7-H1 Antigen:
metabolism / Up-Regulation / Mouth Neoplasms: genetics /
Neoplasm Recurrence, Local: genetics / Head and Neck
Neoplasms / HNSCC (Other) / PD-L1 (Other) / immune
checkpoint inhibitor (Other) / metastases (Other) / oral
cancer (Other) / recurrence (Other) / B7-H1 Antigen (NLM
Chemicals)},
cin = {E221},
ddc = {540},
cid = {I:(DE-He78)E221-20160331},
pnm = {315 - Bildgebung und Radioonkologie (POF4-315)},
pid = {G:(DE-HGF)POF4-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38003576},
pmc = {pmc:PMC10671831},
doi = {10.3390/ijms242216386},
url = {https://inrepo02.dkfz.de/record/285669},
}